PRL-8-53

What Is PRL-8-53?

PRL-8-53 is a synthetic compound (a benzoic-acid methyl-ester derivative) marketed as a research nootropic for memory enhancement. It is not an approved drug or dietary supplement and is sold as a research chemical. Its reputation rests almost entirely on a single small human study from 1978; there is no substantial modern clinical literature, so any claims about it should be read with strong caution.

Evidence

The only primary human trial is Hansl & Mead (1978), a double-blind, placebo-controlled study reporting that a low oral dose improved retention of verbal information (nonsense-syllable learning) to a statistically significant degree, with acquisition only slightly improved ^{1Reference 1Hansl NR · 1978RCTPRL-8-53: enhanced learning and subsequent retention in humans as a result of low oral doses of new psychotropic agent — randomised double-blind placebo-controlled trialView study →}. This is a single, old, small study and has not, to my knowledge, been independently replicated in a modern controlled trial — I did not find any citable modern human RCT of PRL-8-53 in this pass. The compound’s toxicity, long-term safety, and pharmacokinetics in humans are not well characterised. Marketing and nootropic-community write-ups frequently amplify the 1978 result (e.g., “doubled recall”); those secondary summaries are not additional evidence and should not be treated as such.

Dosage & Safety

The single human study used a 5 mg oral dose ^{1Reference 1Hansl NR · 1978RCTPRL-8-53: enhanced learning and subsequent retention in humans as a result of low oral doses of new psychotropic agent — randomised double-blind placebo-controlled trialView study →}; no validated dosing range exists beyond that, and this figure is reported for context, not as a recommendation. PRL-8-53 is a research chemical: it is not an approved medicine or dietary supplement, its purity in consumer products is unverified, and its human safety profile is essentially uncharacterised (toxicity, interactions, and pregnancy safety are not established). This entry is informational only and is not a recommendation to use the compound.

References

1. Hansl NR, Mead BT (1978). PRL-8-53: enhanced learning and subsequent retention in humans as a result of low oral doses of new psychotropic agent — randomised double-blind placebo-controlled trial. Psychopharmacology, 56(3):249–253. https://pubmed.ncbi.nlm.nih.gov/418433/